Summit Therapeutics Inc. Impairment of Intangible Assets (Excluding Goodwill)
Summit Therapeutics Inc. (SMMT) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2025-02-24
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2021-12-31 was $0.00.
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2020-12-31 was $0.00.
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2020-09-30 was $859.00K.
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for fiscal 2022 was $8.47M.
- Summit Therapeutics Inc. impairment of intangible assets (excluding goodwill) for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-24 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-24 | |||
| 2022-12-31 | $8.47M 10-K · filed 2025-02-24 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $859.00K derived: sum of 2 quarters · filed 2022-12-21 | $859.00K 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | $859.00K 10-Q · filed 2021-11-15 | $859.00K 10-Q · filed 2021-11-15 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-16 | $0.00 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |